中文摘要：

目的 评估1550nm铒玻璃点阵激光治疗中重度痤疮的临床疗效和安全性。方法 采用1550nm铒玻璃点阵激光治疗16例中重度痤疮患者。使用点阵密度169点／cm^2，能量密度10mJ／cm^2，首先对活动性皮损照射一遍，然后对整个面部照射一遍，共治疗4次，每次间隔2周。治疗结束后6个月时再抽取其中8例患者进行对照研究，仅对其中有4例接受1次附加治疗，3个月后进行最终疗效评估。结果 有13例患者完成了治疗和随访。治疗结束后6个月时患者评价Burton痤疮评分的平均改善率为68．12％，观察者为81．36％，未使用麻醉药物，未出现不良反应。接受附加1次治疗后的3个月时，接受1次附加治疗组患者评价Burton痤疮评分的平均改善率为80．65％，观察者为84．37％，明显高于未接受附加治疗的患者（68．04％和75．31％），前者明显优于后者，差异均有统计学意义（P均〈0．05）。结论 1550nm铒玻璃点阵激光治疗面部炎性痤疮疗效好，疼痛轻微且无不良反应，增加其维持治疗次数可提高临床疗效。

英文摘要：

Objective To evaluate the effect of the 1 550-nm erbium ： glass fractional laser in the treatment of moderate to severe inflammatory acne on the face. Methods Sixteen patients with moderate to severe ache were treated with the 1 550nm erbium：glass fractional laser （Sellas-Evo,Korea） at 169 spots/cm^2 and 10mJ/cm^2 for 4 times at 2-week intervals. Active lesions were treated before the entire face each time. 8 patients continued in a double-arm study to determine whether an additional treatment at 6 months would prolong the lesion-free period. Final evaluation was at 9 months. Results Thirteen patients completed the study. At 6-month follow-up,patients rated improvement as 68.12%, and the mean investigator improvement assessment was 81.36%. No patients required anesthesia, and no side effects were observed. A single retreatment session after the treatment course held patients improvement assessment as 80. 65% and investigator improvement assessment as 84. 37% at 3-month follow-up, whereas patients without retreatment had 68.04% and 75.31% improvement. The effect of former group was significantly superior to the latter （ P 〈 0. 05 ）. Conclusion Treatment of inflammatory facial ache with the 1 550-nm erbium：glass fractional laser is effective and relatively painless without side effect. Additional treatment sessions may prolong the lesion-free period.